Introduction . The RAS family ( HRAS, NRAS, KRAS ) of oncogenes is a highly sought-after target for cancer therapies1. More than 20% of several major cancer types, including pancreas, lung, and colon are driven by mutations in RAS genes, with KRAS comprising the bulk of those mutations2 , 3 , 4. The most common KRAS mutations occur at codon 12, where the wild-type glycine residue is mutated to a valine (G12V), cysteine (G12C) or aspartate (G12D) residue. For decades...